# A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia

> **NCT05302388** · PHASE1 · COMPLETED · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 45 (actual)

## Conditions studied

- Asymptomatic Hyperuricemia

## Interventions

- **DRUG:** SIBP-R002
- **DRUG:** Dexamethasone or Methyl prednisolone
- **DRUG:** Diphenhydramine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05302388
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2023-01-09
- **Final completion:** 2023-01-09
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05302388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05302388, "A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05302388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*